Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients

J Rheumatol. 1997 Jan;24(1):96-101.

Abstract

Objective: In this study we describe clinical and immunogenetic findings in 62 unselected patients with relapsing polychondritis.

Methods: In a multicenter study, clinical data of 26 (41.9%) female and 36 (58.1%) male patients were collected. HLA-DR specificities were identified in 60, and the frequencies were compared with those in healthy controls.

Results: The median age at the time of diagnosis was 46.6 years (range 17 to 86). 58 (93.5%) patients had auricular chondritis, 31 (50.0%) ocular symptoms, 35 (56.5%) nasal involvement. Involvement of joints (53.2%), respiratory system (30.6%), skin (24.2%), cardiovascular system (22.6%), central nervous system (9.7%), and kidneys (6.5%) was found as well. 22 (35.5%) patients had associated diseases such as systemic lupus erythematosus or rheumatoid arthritis. Susceptibility to relapsing polychondritis was significantly associated with HLA-DR4 (p < 0.001). There was no difference in the frequency or distribution of DRB1*04 subtype alleles between patients and healthy controls. The extent of organ involvement was negatively associated with HLA-DR6 (p < 0.011).

Conclusion: Immunogenetic findings as well as similarities and overlapping clinical symptoms with other autoimmune or rheumatic diseases suggest that immunological mechanisms play a major role in the pathogenesis of relapsing polychondritis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Arthritis / complications
  • Cardiovascular Diseases / complications
  • Ear Diseases / complications
  • Eye Diseases / complications
  • Female
  • Fever / complications
  • Follow-Up Studies
  • HLA-DR Antigens / analysis
  • Humans
  • Kidney Diseases / complications
  • Male
  • Middle Aged
  • Nervous System Diseases / complications
  • Nose Diseases / complications
  • Polychondritis, Relapsing / complications
  • Polychondritis, Relapsing / diagnosis
  • Polychondritis, Relapsing / immunology*
  • Weight Loss / immunology

Substances

  • HLA-DR Antigens